论文部分内容阅读
目的探讨蛋白磷酸酶2A癌性抑制因子(CIP2A)在慢性粒细胞白血病(CML)中的表达及意义。方法采用免疫组织化学SP法同时测定CIP2A、β-catenin和C-myc在对照组和CML各期中的表达,并分析CIP2A、β-catenin和C-myc表达的关系。结果①CIP2A、β-catenin和C-myc在CML-AP/BP组的表达显著高于CML-CP组和对照组(P<0.05),CML-CP组和对照组差异无统计学意义(P>0.05),CIP2A、β-catenin和C-myc在CML的表达均成正相关关系(P<0.05)。②CIP2A在未缓解组的表达显著高于缓解组(P<0.05)。结论 CIP2A高表达可能是CML发生急变的机制之一,这个过程可能是通过上调C-myc实现的,而且CIP2A高表达与化疗疗效密切相关。
Objective To investigate the expression of CIP2A and its significance in chronic myeloid leukemia (CML). Methods The expressions of CIP2A, β-catenin and C-myc were detected by immunohistochemical SP method in the control and CML stages. The relationship between CIP2A, β-catenin and C-myc expression was analyzed. Results ① The expressions of CIP2A, β-catenin and C-myc in CML-AP / BP group were significantly higher than those in CML-CP group and control group (P <0.05). There was no significant difference between CML-CP group and control group (P> 0.05). There was a positive correlation between CIP2A, β-catenin and C-myc expression in CML (P <0.05). ② The expression of CIP2A in non-remission group was significantly higher than that in remission group (P <0.05). Conclusion CIP2A overexpression may be one of the mechanisms of CML mutation. This process may be achieved by up-regulation of C-myc, and CIP2A overexpression is closely related to the efficacy of chemotherapy.